Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
10:36am, Wednesday, 30'th Jul 2025
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics com
Teva Pharm Q2 profit beats estimates as branded drugs gain
07:21am, Wednesday, 30'th Jul 2025
Teva Pharmaceutical Industries reported a higher than expected rise in second-quarter profit, helped by strong sales gains of its branded drugs to treat migraines, Huntington's disease and schizophren
Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
02:44pm, Tuesday, 29'th Jul 2025
Teva Pharmaceutical Industries Ltd. TEVA will release its second-quarter 2025 financial results tomorrow, July 30.
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
01:06am, Tuesday, 29'th Jul 2025
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Teva Pharmaceutical Industries (TEVA), delve into some of its key metrics to gain a deeper insight into the company's potential
Though earnings season is often viewed as the highlight of each quarter, there are a number of other data releases that can tell investors a lot about the health of the stock market. In particular, th
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
09:36am, Friday, 11'th Jul 2025
TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.
Billionaire Stanley Druckenmiller Sold Palantir And Buying This Stock Instead
05:20pm, Tuesday, 01'st Jul 2025
Billionaire investment legend Stanley Druckenmiller is quickly becoming one of my favorite big-money managers to follow quarter to quarter.
Teva Releases Q2 2025 Aide Memoire
04:30pm, Thursday, 26'th Jun 2025
TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
04:30pm, Wednesday, 25'th Jun 2025
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial re
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
08:44am, Wednesday, 25'th Jun 2025
Stanley Druckenmiller made a fortune working alongside billionaire George Soros. He ran his own hedge fund for years before closing it in 2010.
TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevent
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
01:06pm, Tuesday, 17'th Jun 2025
TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
09:03am, Monday, 16'th Jun 2025
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established wit
There's nothing more valuable on Wall Street than data, and investors rarely have to dig to find something that's pertinent to the U.S. economy, the stock market, or their specific portfolio holdings.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
11:46am, Tuesday, 10'th Jun 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Richard D. Francis - President, CEO & Director
